A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Clinical trial NCT01498328 · COMPLETED

Trial details

NCT number: NCT01498328
Sponsor: Celldex Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Glioblastoma Small Cell Glioblastoma Giant Cell Glioblastoma Gliosarcoma Glioblastoma With Oligodendroglial Component Recurrent Glioblastoma Relapsed Glioblastoma

Start date: 2011-12-01
Primary completion: 2015-04-01
Enrollment: 127

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.